U.S. Retail REITs Stock News

WhiteFiber, Inc. has reported its Q1 2026 results, with revenue rising to US$21.92 million while the company moved from a prior net profit to a US$12.04 million net loss and a basic loss per share of US$0.31. Alongside earnings, WhiteFiber accelerated its data center and AI infrastructure buildout, funded partly by US$230 million of 4.50% convertible senior notes and the purchase of additional facility ownership to support future capacity. Next, we’ll examine how this loss-making quarter,...

Figma (FIG) opened Q1 2026 with total revenue of US$333.4 million and a basic EPS loss of US$0.27, while trailing 12 month revenue reached US$1.2 billion against a trailing EPS loss of US$3.38 and year on year revenue growth of 41.4%. Over recent quarters, the company has seen revenue move from US$216.9 million in Q4 2024 to US$333.4 million in Q1 2026. Quarterly EPS has swung between a profit of US$0.46 in Q4 2024 and a loss of US$2.72 in Q3 2025 before landing at a loss of US$0.27 this...

Empire Petroleum (EP) opened 2026 with Q1 revenue of about US$5.1 million and a basic EPS loss of US$0.18, while the trailing twelve months show revenue of roughly US$30.3 million and a basic EPS loss of US$2.15. Over recent quarters the company has seen revenue move from US$12.97 million in Q4 2024 to US$9.00 million in Q1 2025 and US$5.10 million in Q1 2026, alongside a shift in quarterly basic EPS losses from US$0.13 to US$0.12 and then US$0.18. This keeps the focus on how efficiently each...

Harmony Biosciences Holdings, Inc. reported past first-quarter 2026 results on May 7, with net income of US$32.49 million, down from US$45.56 million a year earlier, and basic earnings per share from continuing operations of US$0.56 versus US$0.79. Alongside this earnings miss, the company highlighted 17% net product revenue growth, fresh FDA approval for a pediatric cataplexy indication, and active legal efforts to protect WAKIX patents into 2030. We’ll now examine how robust revenue growth...

Recent performance snapshot FactSet Research Systems (FDS) has come under pressure recently, with the stock down over the past month and year to date, while still showing a modest gain over the past 3 months. That mixed share performance sits alongside annual revenue of US$2.4b and net income of US$587.8m, as investors weigh the company’s role as a financial data and analytics platform serving asset managers, banks, and other investment professionals worldwide. See our latest analysis for...

Johnson & Johnson (JNJ) just reported quarterly earnings and sales ahead of expectations, supported by both its Innovative Medicines and MedTech segments, while raising 2026 guidance and extending its dividend growth streak to 64 years. See our latest analysis for Johnson & Johnson. Despite the earnings beat and steady dividend record, the stock is trading at US$226.71, with the share price down 5.01% over 30 days and 6.88% over 90 days. The 1-year total shareholder return of 53.99% and...

Earlier in May 2026, Realty Income reported higher first-quarter revenue of US$1,548.73 million and net income of US$311.77 million year over year, modestly lowered full-year 2026 net income per-share guidance, and completed US$99.3 million of share repurchases alongside fresh follow-on and at-the-market equity offerings. The company also advanced its private capital and acquisition agenda by completing a US$1.70 billion cornerstone capital raise, lifting full-year investment guidance to...

Why CECO Environmental Stock Is On Investors’ Radar CECO Environmental (CECO) has caught investor attention after a strong share price run, with the stock up about 25% over the past month and about 2% over the past 3 months. See our latest analysis for CECO Environmental. That recent 25% 1 month share price return comes after a quieter 3 month move and sits alongside a 35% year to date share price gain and a very large 5 year total shareholder return. Together, these point to strong longer...

Earlier this week, JD.com reported first-quarter 2026 results showing revenue of CNY 315.69 billion and net income of CNY 5.10 billion, with earnings per share from continuing operations roughly halving year on year. At the same time, JD.com completed a major buyback program repurchasing 227.70 million shares, about 15.87% of its share base, signaling management’s confidence while it invests in automation, AI logistics, and higher-margin services. Next, we’ll examine how JD.com’s strong Q1...

Ingredion (NYSE:INGR) has entered takeover talks to acquire Tate & Lyle in an all cash deal. The potential transaction is valued at about US$3.7b and would combine two major players in sweeteners and specialty food ingredients. The discussions confirm a formal approach, although there is no announced agreement or timeline for completion. For investors watching NYSE:INGR, this move centers on core products like sweeteners, starches, and specialty ingredients that feed into food, beverage,...

In the past week, Aehr Test Systems reported mixed fiscal third-quarter 2026 results amid sector uncertainty and recent share dilution from a US$60,000,000 equity offering, while insiders filed and amended several Form 4 and Form 144 disclosures including gifts, sales, and potential resale notices. An interesting angle is that these routine yet sizable insider and equity-related filings are intersecting with questions about AI chip demand strength and company backlog, sharpening investor...

Applied Digital recently closed a US$300 million senior secured bridge facility led by Goldman Sachs to support construction of its third AI data center at the Polaris Forge 1 campus in Ellendale, North Dakota. A separate 15-year, US$7.5 billion lease with an investment-grade U.S. hyperscaler at the Delta Forge 1 campus substantially expands Applied Digital’s contracted revenue base while it retains upside through its ownership stake in the newly formed ChronoScale Corporation. We’ll now...

Recent performance snapshot Texas Capital Bancshares (TCBI) stock has seen mixed returns recently, with the share price near $95.98 and moves that include a decline over the past month and past 3 months, alongside stronger longer term total returns. See our latest analysis for Texas Capital Bancshares. Short term momentum has faded, with the share price down 7.2% over 3 months, yet the 1 year total shareholder return of 26.6% and 3 year total shareholder return of 95.6% show a stronger longer...

If you are wondering whether Wix.com at US$52.71 is starting to look like value or still carries too much risk, the recent share price performance gives you plenty to think about. The stock has fallen 34.4% over the past week, 17.4% over the last month, 47.8% year to date, 71.2% over one year, 34.7% over three years, and 78.7% over five years, which may change how you think about its potential and the risks involved. Recent coverage around Wix.com has focused on how the stock's sharp...

Aeluma (NasdaqCM:ALMU) has just posted its Q3 2026 numbers, reporting revenue of US$1.2 million and a loss of US$1.8 million, or EPS of US$0.10. This sets a cautious tone for shareholders at the current US$26.65 share price. Over recent quarters the company has reported revenue between US$1.3 million and US$1.6 million, while EPS has shifted from a profit of US$0.12 in Q3 2025 to losses of around US$0.09 to US$0.24 per share. This has kept margins under clear pressure and made profitability...

Recent share performance and business overview Liquidia (LQDA) has drawn fresh attention after recent trading, with the stock’s moves prompting investors to reassess how its rare cardiopulmonary drug portfolio and clinical programs align with their own risk and return expectations. See our latest analysis for Liquidia. Recent trading sits within a much stronger backdrop, with a 30 day share price return of 53.19% and a 1 year total shareholder return of 207.25%. This points to powerful...

Nuvation Bio Inc. recently completed the process technology transfer and product introduction to Thermo Fisher Scientific for IBTROZI (taletrectinib), enabling Thermo Fisher to manufacture the ROS1-positive NSCLC therapy in the United States and support reliable drug supply. Away from the clinic, Thermo Fisher has also been broadening its platform with launches such as the Gibco CTS DynaXS Single Use Bioreactor and Nalgene’s Fresh Flow straw bottle, underscoring its reach from advanced cell...

Why OneMain Holdings Stock Is Back on Investors’ Radar OneMain Holdings (OMF) has drawn fresh attention after reporting first quarter net income of US$226 million, completing a US$141.58 million buyback tranche, and attracting a 4.8% passive stake from Capital International Investors. See our latest analysis for OneMain Holdings. The recent earnings update and completion of the US$141.58 million buyback come after a period where the share price has fallen 21.89% year to date, even as the 1...

Axsome Therapeutics (AXSM) is back in focus after detailing plans to launch AUVELITY for Alzheimer’s disease agitation in June, supported by a larger sales force and expectations of broad Medicare Part D coverage. See our latest analysis for Axsome Therapeutics. The June AUVELITY launch plan for Alzheimer’s agitation and recent first quarter 2026 earnings have arrived alongside strong momentum, with a 30 day share price return of 26.11% and a one year total shareholder return of 116.63%. If...

SELLAS Life Sciences Group (NasdaqCM:SLS) is nearing the pivotal Phase 3 data readout for galinpepimut-S in the REGAL trial for acute myeloid leukemia (AML). The company has also initiated a Phase 2 trial of its CDK9 inhibitor SLS009 in newly diagnosed, high-risk AML patients. These clinical milestones mark a key moment for the company’s AML program and broader oncology pipeline. SELLAS Life Sciences Group focuses on late-stage, oncology-focused drug candidates, with galinpepimut-S and...

Concentrix (CNXC) is back in focus as investors weigh its upcoming appearance at the Needham Technology, Media, & Consumer Conference in light of ongoing worries about AI disruption, softer growth trends, and higher leverage from the Webhelp acquisition. See our latest analysis for Concentrix. The recent share price tells a cautious story, with Concentrix at US$23.42 after a 1 month share price return down 17.19% and year to date share price return down 43.17%. This mirrors a 1 year total...

Tron Inc. reported first-quarter 2026 results, with sales of US$1.18 million versus US$1.09 million a year earlier and net income of US$21.63 million compared with a net loss in the prior-year period. This shift from a loss per share to positive basic earnings per share from continuing operations highlights a sharp improvement in Tron's profitability profile. We will now examine how Tron's return to profitability in the latest quarter shapes the company's broader investment narrative and...

Omeros (OMER) opened 2026 with Q1 revenue of US$9.9 million and basic EPS of US$0.71, alongside net income from continuing operations of US$51.2 million, setting a clear earnings focused tone for the quarter. Over recent periods, the company has seen quarterly revenue move from US$0 to US$9.9 million while quarterly EPS has ranged from a loss of US$0.65 to a gain of US$1.13, giving investors a wide band of outcomes to weigh as they assess how much of the latest profit is repeatable versus...

Earlier this month, Critical Metals Corp. received formal approval from the Government of Greenland to acquire a 70% stake in 60 North Greenland ApS, advancing control over key land and assets linked to its Tanbreez rare earth and hafnium project. This approval, together with plans for a Romanian hafnium refinery geared to EU, NATO and US customers, underlines Critical Metals’ role in efforts to reshape Western supply chains for this tightly constrained metal. We’ll now examine how...